[HTML][HTML] Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international …

KM Kunisaki, DE Niewoehner, G Collins… - The Lancet …, 2016 - thelancet.com
Background Observational data have been conflicted regarding the potential role of HIV
antiretroviral therapy (ART) as a causative factor for, or protective factor against, COPD. We …

Urinary incontinence in chronic obstructive pulmonary disease: a common co-morbidity or a typical adverse effect?

S Battaglia, A Benfante, S Principe, L Basile… - Drugs & aging, 2019 - Springer
Urinary incontinence (UI) is defined as a loss of bladder control and is characterized by the
complaint of any involuntary leakage of urine. Evidence suggests that the prevalence of UI is …

[HTML][HTML] COPD treatment–a conceptual review based on critical endpoints

A Roque, L Taborda-Barata, ÁA Cruz, G Viegi… - Pulmonology, 2023 - Elsevier
Introduction Chronic obstructive pulmonary disease (COPD) is one of the main causes of
death and disability worldwide. Many treatment options are now available, but criteria for …

Long-term inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease, cardiovascular disease, and a recent hospitalised exacerbation …

A Papi, G Forini, M Maniscalco, E Bargagli… - European Journal of …, 2024 - Elsevier
Introduction Patients with chronic obstructive pulmonary disease (COPD) frequently have
cardiovascular comorbidities, increasing the risk of hospitalised COPD exacerbations (H …

The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients

M Malerba, M Nardin, A Radaeli… - Expert review of …, 2017 - Taylor & Francis
Introduction: Despite lack of knowledge in the field, several studies have underlined the role
of endothelium dysfunction and platelet activation as significant players in the development …

[HTML][HTML] Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: the SUMMIT trial

C Crim, PMA Calverley, JA Anderson, AP Holmes… - Respiratory …, 2017 - Elsevier
Rationale Pneumonia risk with inhaled corticosteroid use in chronic obstructive pulmonary
disease (COPD) has not been thoroughly assessed in patients with moderate airflow …

[HTML][HTML] Effect of fracture risk in inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

S Peng, C Tan, L Du, Y Niu, X Liu, R Wang - BMC Pulmonary Medicine, 2023 - Springer
Background The fracture risk of patients with chronic obstructive pulmonary disease (COPD)
treated with inhaled corticosteroids is controversial. And some large-scale randomized …

The long-term burden of COPD exacerbations during maintenance therapy and lung function decline

M Kerkhof, J Voorham, P Dorinsky… - … journal of chronic …, 2020 - Taylor & Francis
Introduction Early identification of preventable risk factors of COPD progression is important.
Whether exacerbations have a negative impact on disease progression is largely unknown …

[Translated article] Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care

JL Lopez-Campos, P Almagro, JT Gómez… - Archivos de …, 2022 - Elsevier
The current health care models described in GesEPOC indicate the best way to make a
correct diagnosis, the categorization of patients, the appropriate selection of the therapeutic …

Left ventricular volume and wall stress are linked to lung function impairment in COPD

P Alter, RA Jörres, H Watz, T Welte, S Gläser… - International journal of …, 2018 - Elsevier
Background Cardiovascular comorbidities are common in chronic obstructive pulmonary
disease (COPD). We examined the association between airflow limitation, hyperinflation and …